Company Overview

Lisata Therapeutics, Inc. is a clinical-stage oncology biotechnology company focused on developing novel therapies designed to improve the delivery and effectiveness of cancer treatments. The company operates within the biopharmaceutical and oncology drug development industries, with a primary emphasis on solid tumors that are difficult to treat due to poor drug penetration. Lisata’s core strategy centers on tumor-penetrating technology intended to enhance the efficacy of existing anti-cancer agents rather than replacing them.

The company’s primary product candidate is CEND-1, a cyclic peptide designed to modify the tumor microenvironment and improve intratumoral drug uptake when administered alongside standard-of-care therapies. Lisata’s lead clinical focus is pancreatic ductal adenocarcinoma, with additional exploratory work in other solid tumors. The company traces its history to its prior incarnation as Caladrius Biosciences, Inc., before rebranding as Lisata Therapeutics, Inc. to reflect a strategic pivot toward oncology and tumor-penetrating therapeutics.

Business Operations

Lisata’s operations are organized around a single reportable operating segment focused on oncology drug development, with revenue generation currently limited, as the company remains in the clinical development stage. The company does not market approved products and relies primarily on capital markets financing to fund research and development activities. Clinical trials are conducted through third-party contract research organizations, academic institutions, and clinical sites.

The company’s principal asset, CEND-1, is based on a proprietary tumor-penetrating peptide platform originally derived from the iRGD peptide technology. Lisata does not maintain manufacturing facilities and instead utilizes external partners for clinical supply production. Operations are primarily domestic, with international clinical trial activity depending on study design and regulatory requirements. Public disclosures do not indicate any material joint ventures, and subsidiaries, if any, are not operationally distinct based on available public filings.

Strategic Position & Investments

Lisata’s strategic direction is centered on positioning CEND-1 as a combination-enabling agent that can be paired with chemotherapy, targeted therapies, or immunotherapies to enhance their effectiveness. Growth initiatives are focused on advancing clinical trials, generating proof-of-concept data, and expanding the potential application of its tumor-penetrating platform across multiple oncology indications.

The company has historically grown through internal development rather than large-scale acquisitions, and public disclosures do not identify material recent acquisitions or portfolio investments. Strategic collaborations are primarily clinical or research-based, rather than equity investments. Lisata’s technology places it within the emerging field of tumor microenvironment modulation, a sector aimed at overcoming biological barriers to effective cancer treatment.

Geographic Footprint

Lisata Therapeutics is headquartered in the United States, with its principal executive offices located in New Jersey. The company’s operational footprint is relatively lean, reflecting its status as a clinical-stage biotechnology firm without commercial manufacturing or sales infrastructure.

Clinical development activities extend beyond the United States through international trial sites as required, though the company does not report significant standalone international operations. Its market presence is primarily tied to global capital markets and the international oncology research ecosystem rather than direct commercial activity across continents.

Leadership & Governance

Lisata is led by an executive team with experience in pharmaceutical development, oncology, and biotechnology finance. The leadership emphasizes capital discipline, clinical execution, and strategic partnerships to advance its lead asset efficiently through development stages. Governance follows standard public biotechnology company practices, with oversight by a board of directors.

Key executives include:

• David J. Mazzo – President and Chief Executive Officer
• Michael Handley – Chief Financial Officer
• Kristen Albright – Chief Development Officer
• Peter O’Heeron – Chief Medical Officer

The company’s leadership philosophy is oriented toward advancing differentiated science while managing development risk through staged clinical validation and prudent financial management.